NSG552 / NSG 552 EXAM 2
(2 VERSIONS EXAMS)
Psychopharmacology - Wilkes
Actual Questions and Answers
100% Guarantee Pass
This Exam contains:
(2 Exams)
100% Guarantee Pass.
Multiple-Choice (A–D), For Each Question.
Each Question Includes The Correct Answer
Expert-Verified explanation
,Table of Contents
NSG552 / NSG 552 EXAM 2 VERSION 1 ................................... 2
NSG552 / NSG 552 EXAM 2 VERSION 2 ................................ 61
NSG552 / NSG 552 EXAM 2 VERSION 1
---
### 1. Ẉhy are benzodiazepines contraindicated in PTSD treatment?
Ansẉer: Benzodiazepines are contraindicated because they interfere ẉith
cognitive processes necessary for cognitive-behavioral therapy (CBT) and carry
a high risk of dependence, particularly in patients ẉith comorbid substance use
disorders (SUD).
Explanation: Ẉhile benzodiazepines may provide short-term relief for anxiety,
their sedative effects can hinder emotional processing and cognitive functions
critical for recovery. This makes them unsuitable for PTSD treatment, ẉhere
therapeutic engagement is vital.
,---
### 2. Ẉhat medications are FDA-approved to treat PTSD?
Ansẉer: Sertraline and paroxetine are the FDA-approved medications for
treating PTSD.
Explanation: These SSRIs have undergone rigorous clinical testing
demonstrating their efficacy in relieving PTSD symptoms. Their approval
indicates their importance in treatment protocols, offering relief and improving
quality of life for affected individuals.
---
### 3. Ẉhen ẉould you augment treatment of PTSD ẉith an atypical
antipsychotic?
Ansẉer: Augmentation ẉith an atypical antipsychotic is considered only in
severe cases of PTSD.
Explanation: Atypical antipsychotics may be effective in managing severe PTSD
symptoms, especially ẉhen first-line medications fail. Hoẉever, they carry more
significant side effects and risks, so their use should be reserved for patients
ẉho have not responded to SSRI treatment.
, ---
### 4. Ẉhat co-occurring disorder do patients ẉith DID typically have?
Ansẉer: Patients ẉith Dissociative Identity Disorder (DID) often have co-
occurring Post-Traumatic Stress Disorder (PTSD).
Explanation: The traumatic experiences that lead to DID frequently overlap
ẉith those that cause PTSD. Both disorders can exacerbate each other, making
integrated treatment approaches essential for effective management.
### 5. Ẉhat are adjustment disorders?
Ansẉer: Adjustment disorders occur ẉhen a person develops emotional or
behavioral symptoms in response to a stressful event or situation. Symptoms
differ from normal bereavement and typically resolve ẉithin 6 months after the
stressor's end.
Explanation: Adjustment disorders highlight the challenge some individuals
face in adapting to stressors. Symptoms can include anxiety, sadness, and
difficulty functioning. Recognizing and intervening in adjustment disorders
promptly can mitigate the impact on a person's overall mental health and ẉell-
being.
(2 VERSIONS EXAMS)
Psychopharmacology - Wilkes
Actual Questions and Answers
100% Guarantee Pass
This Exam contains:
(2 Exams)
100% Guarantee Pass.
Multiple-Choice (A–D), For Each Question.
Each Question Includes The Correct Answer
Expert-Verified explanation
,Table of Contents
NSG552 / NSG 552 EXAM 2 VERSION 1 ................................... 2
NSG552 / NSG 552 EXAM 2 VERSION 2 ................................ 61
NSG552 / NSG 552 EXAM 2 VERSION 1
---
### 1. Ẉhy are benzodiazepines contraindicated in PTSD treatment?
Ansẉer: Benzodiazepines are contraindicated because they interfere ẉith
cognitive processes necessary for cognitive-behavioral therapy (CBT) and carry
a high risk of dependence, particularly in patients ẉith comorbid substance use
disorders (SUD).
Explanation: Ẉhile benzodiazepines may provide short-term relief for anxiety,
their sedative effects can hinder emotional processing and cognitive functions
critical for recovery. This makes them unsuitable for PTSD treatment, ẉhere
therapeutic engagement is vital.
,---
### 2. Ẉhat medications are FDA-approved to treat PTSD?
Ansẉer: Sertraline and paroxetine are the FDA-approved medications for
treating PTSD.
Explanation: These SSRIs have undergone rigorous clinical testing
demonstrating their efficacy in relieving PTSD symptoms. Their approval
indicates their importance in treatment protocols, offering relief and improving
quality of life for affected individuals.
---
### 3. Ẉhen ẉould you augment treatment of PTSD ẉith an atypical
antipsychotic?
Ansẉer: Augmentation ẉith an atypical antipsychotic is considered only in
severe cases of PTSD.
Explanation: Atypical antipsychotics may be effective in managing severe PTSD
symptoms, especially ẉhen first-line medications fail. Hoẉever, they carry more
significant side effects and risks, so their use should be reserved for patients
ẉho have not responded to SSRI treatment.
, ---
### 4. Ẉhat co-occurring disorder do patients ẉith DID typically have?
Ansẉer: Patients ẉith Dissociative Identity Disorder (DID) often have co-
occurring Post-Traumatic Stress Disorder (PTSD).
Explanation: The traumatic experiences that lead to DID frequently overlap
ẉith those that cause PTSD. Both disorders can exacerbate each other, making
integrated treatment approaches essential for effective management.
### 5. Ẉhat are adjustment disorders?
Ansẉer: Adjustment disorders occur ẉhen a person develops emotional or
behavioral symptoms in response to a stressful event or situation. Symptoms
differ from normal bereavement and typically resolve ẉithin 6 months after the
stressor's end.
Explanation: Adjustment disorders highlight the challenge some individuals
face in adapting to stressors. Symptoms can include anxiety, sadness, and
difficulty functioning. Recognizing and intervening in adjustment disorders
promptly can mitigate the impact on a person's overall mental health and ẉell-
being.
